Zealand Pharma A/S ranks in the top quartile of its peer group, with stability as the main structural constraint. The market setup has weakened, with clear trend damage and relative performance under pressure. Price action is not yet fully confirming the underlying structural profile.
Peer-relative scores, weakest to strongest
Zealand Pharma develops peptide-based drugs targeting obesity and metabolic disorders. The company is advancing several candidates through Phase II and III clinical trials.
ZEAL is priced as a high-risk pipeline play, not a quality leader. With an operating margin of -38%—typical for biotech but strong relative to peers—the market focuses on the 61.5% one-year volatility, interpreting each clinical milestone as a signal for future prospects rather than rewarding operational progress. ZEAL’s focus on innovative obesity therapies with ongoing Phase II/III programs means the market reacts to binary trial outcomes, repricing the stock sharply with each event rather than reflecting steady business performance. Rather than embedding quality returns into the valuation, the market consistently recalibrates ZEAL’s price around event risk, so even positive surprises are met with renewed volatility instead of lasting stability. A disappointing trial result or regulatory setback triggers a sharp rerating.
Break down ZEAL.CO's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.